Abstract

Neuroinflammation has emerged as a key player in Alzheimer’s disease, frontotemporal dementia, and related disorders. A range of anti-inflammatory treatments could be helpful to slow or prevent decline in people with these conditions. However, immunotherapeutic strategies are hampered by lack of knowledge about individual differences in inflammation, their causes and consequences. Using PET imaging we can now localise and quantify in vivo brain inflammation in patients, validating post-mortem evidence – while fluid-based inflammatory markers are investigated to clarify the interaction between central and peripheral inflammation. This talk will review research progress in inflammation biomarkers in dementia, and how a multidisciplinary approach integrating imaging, fluid markers and post-mortem evaluation is crucial to understand the complex framework of neuroinflammation in dementia.